"FreeSlate builds upon a tradition of enabling scientific R&D organizations to accelerate the pace of discovery while reducing costly, complex procedures that hinder efficiency," said John Senaldi, FreeSlate's chief executive officer.
Quotation
Another Pfizer Phase III program goes bust
Submitted by Anonymous on Thu, 04/03/2010 - 17:25How many more of these late stage clinical trials that have been promoted as helping Pfizer to avert the Liptor cliff will Pfail? Per Freddy Mercury..."and another ones gone, and another ones gone, another one bites the dust."
1,200 jobs go with AstraZeneca closure
Submitted by Anonymous on Tue, 02/03/2010 - 16:19AROUND 1,200 jobs are to be lost with the closure of one of Loughborough's biggest employers.
AstraZeneca today announced it is to shut its pharmaceutical plant in the town next year.
Staff were told this afternoon.
Loughborough MP Andy Reed said: "The word devastating is over used but I think that is the only way to describe this."
PFE Sandwich
Submitted by Anonymous on Tue, 02/02/2010 - 21:46Get shot of FTES and let the lab space!
Peakdale Molecular Partners With Pfizer
Drug Discovery & Development - February 01, 2010
Spectrum and Topotarget
Submitted by Anonymous on Tue, 02/02/2010 - 11:28- The Rumor Mill
- Biotechnology
- biotechnology
- California
- cancer
- Company Technology
- Company Ticker
- Conference Call
- FDA
- Irvine
- National Cancer Institute
- paclitaxel
- Peripheral T-Cell Lymphoma
- Person Career
- Quotation
- Spectrum Pharmaceuticals
- TopoTarget A/S
- TopoTarget Will Jointly Fund
- tumors
- U.S. Food and Drug Administration
Spectrum buying into cancer drug which is potential blockbuster. Not cheap, but probably worth it...
Spectrum Pharmaceuticals Licenses Belinostat, a Novel Anticancer Drug in a Pivotal Registrational Trial
•Belinostat, a HDAC Inhibitor, is Currently in a Multicenter, Registrational Trial Under a Special Protocol Assessment for Peripheral T-Cell Lymphoma (PTCL)
Lucifer at it again! Life Tech Denies Breach-of-Contract Claims in Suit by Former Visigen CEO
Submitted by Anonymous on Tue, 19/01/2010 - 22:44Life Technologies last week denied all allegations in a lawsuit that former Visigen Biotechnologies CEO and co-founder Susan Hardin filed in October 2009 against Life Tech, its Invitrogen unit, and Visigen, alleging breach of contract, fraud, negligent representation, and breach of fiduciary duty regarding Invitrogen's 2008 acquisition of Visigen.
Row over `haste' in allowing Ph.D seminar
Submitted by Anonymous on Mon, 18/01/2010 - 15:30Row over `haste' in allowing Ph.D seminar
Yogindra Mohan
PATIALA. The Punjabi University here seems set to create a record of sorts by allowing a research scholar to present his pre-thesis submission seminar for grant of a doctorate degree within three months of his registration in the Department of Biotechnology.
New Illumina Sequencer
Submitted by Anonymous on Wed, 13/01/2010 - 05:03How will this stack up to Complete Gen and Pac Bio?
Pfizer / Wyeth what's going on?
Submitted by Anonymous on Mon, 14/09/2009 - 21:20I have heard that the first week of October is when the deal will be sealed. Day 1 will be 30 days later.
Fluidigm circling the drain?
Submitted by Anonymous on Thu, 13/08/2009 - 09:00- The Rumor Mill
- California Institute for Regenerative Medicine
- Company Investment
- Company Location
- Company Technology
- Fluidigm
- genetic analysis systems
- genetic services
- genotyping
- Howard High Fluidigm
- Person Career
- Quotation
- regenerative medicine
- Securities and Exchange Commission
- Singapore
- South San Francisco
- Stanford
- Stem cells
- Stephen Quake
- USD
They just closed their microfluidic fab. Are Fluidigms days numbered?
